Who Paid My Doc
Genmab BV
Netherlands
CMS manufacturer 100001351960
General payments
$189,681
Research payments
$955,866
Ownership & investment interest
$0
Through program year 2025, Genmab BV reported paying $189,681 in general payments and $955,866 in research payments to U.S. physicians, teaching hospitals and other recipients.
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $138,181 | 3 |
| 2025 | Research | $272,724 | 16 |
| 2024 | General | $51,500 | 4 |
| 2024 | Research | $306,176 | 73 |
| 2023 | Research | $376,966 | 125 |
Breakdown
Each share is of this company’s general payments in 2025 where a state was reported.
Grouped by name only. CMS publishes no corporate ownership, so a shared name does not mean a shared parent.
Records
7 general · 214 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.